Efficacy of dendritic cells/cytokine induced killer cells adoptive immunotherapy combined with chemotherapy in treatment of metastatic colorectal cancer

Chinese Journal of Cancer Biotherapy

Volumn 20, Issue 2, 2013, Pages 217-224

  Yin, Liangwei ^a   Wang, Suping ^a   Zhang, Li ^a   Wang, Ying ^a   Ji, Jun ^a   Wang, Heshuang ^a   Guo, Xu ^a   Wang, Xiaohong ^a   Ma, Shubei ^a   Du, Xiaohong ^a   Ma, Haiying ^b  

^a Cell Biological Treatment Ward Dalian Centre Hospital ^*  (China)

^b DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Adoptive immunotherapy; Chemotherapy; DC CIK; Metastatic colorectal cancer (mCRC)

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA INTERFERON; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DENDRITIC CELL; DIARRHEA; DISEASE CONTROL; HUMAN; LEUKOPENIA; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE;

EID: 84940356602     PISSN: 1007385X     EISSN: None     Source Type: Journal    
DOI: 10.3872/j.issn.1007-385X.2013.02.016     Document Type: Article

References (32)

1. Chen HM, Weng YR, Jiang B, et al. Epidemiological study of colorectal adenoma and cancer in symptomatic patients in China between 1990 and 2009 [J]. J Dig Dis, 2011, 12(5): 371-378.
2. Brenner MK, Heslop HE. Adoptive T cell therapy of cancer [J]. Curr Opin Immunol, 2010, 22(2): 251-257.
3. Mesiano G, Todorovic M, Gammaitoni L, et al. Gytokine-induced killer (GIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors [J]. Expert Opin Biol Ther, 2012, 12(6): 673-684.
4. Bernatchez G, Radvanyi LG, Hwu P. Advances in the treatment of metastatic melanoma: Adoptive T-cell therapy [J]. Semin Oncol, 2012, 39(2): 215-226.
5. Cruz GR, Hanley PJ, Liu H, et al. Adverse events following infusion of T cells for adoptive immunotherapy: A 10 year experience [J]. Gytotherapy, 2010, 12(6): 743-749.
6. Di L, Zhu Y, Jia J, et al. Clinical safety of induced GTL infusion through recombinant adeno-associated virus-transfected dendritic cell vaccination in Chinese cancer patients [J]. Clin Transl Oncol, 2012, 14(9): 675-681.
7. Montagna D, Turin I, Schiavo R, et al. Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cyto-toxic T lymphocytes in patients with solid tumor [J]. Cytotherapy, 2012, 14(1): 80-90.
8. Adams SO, Neill DW, Bhardwaj N. Recent ad vances in dendritic cell biology [J]. J Clin Immunol, 2005, 25(2): 87-98.
9. Hegmans JP, Veltman JD, Lambers ME, et al. Consolidative dendritic cell- based immunotherapy elicits cytotoxicity against malignant mesothelioma [J]. Am J Respir Crit Care Med, 2010, 181 (12): 1383-1390.
10. Thara E, Dorff TB, Pinski JK, et al. Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer [J]. Materitas, 2011, 69(4): 296-303.
11. Couzin-Frankel J. Immune therapy steps up the attack [J]. Science, 2010, 330(6003): 440-443.
12. Janikashvili N, Larmonier N, Katsanis E. Personalized dendritic cell-based tumor immunotherapy [J]. Immunotherapy, 2010, 2 (1): 57-68.
13. Levings MK, Gregori S, Tresoldi E, et al. Differentiation of Trl cells by immature dendritic cells requires IL-10 but not CD25 + CD4+ Tr cells [J]. Blood, 2005, 105(3): 1162-1169.
14. Mehta BA, Schmidt-Wolf IG, Weissman IL, et al. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine- induced CD3 + CD56+ killer cells [J]. Blood, 1995, 86(9): 3493-3499.
15. Hoyle C, Bangs CD, Chang P, et al. Expansion of Philadelphia chromosome- negative GD3 (+) CD56 (+) cytotoxic cells from chronic myeloid leukemia patients: In vitro and in vivo efficacy in severe combined immunodeficiency disease mice [J]. Blood, 1998, 92(9): 3318-3327.
16. Verneris MR, Kornacker M, Mailánder V, et al. Resistance of ex vivo expanded GD3 + CD56+ T cells to Fas-mediated aDODtosis [J]. Cancer Immunol Immunother, 2000, 49(6): 335-345
17. Peqqs KS, Quezada SA, Allison JP. Cancer immunotherapy: Co-stimulatoryagonists and co-inhibitory antagonists [J]. Glin Exp Immunol, 2009, 57(1): 9-19.
18. Amedei A, Niccolai E, D'Elios MM. T cells and adoptive immunotherapy: Recent developments and future prospects in gastrointestinal oncology [J]. Glin Dev Immunol, 2011, 2011: 320571.
19. Iwai K, Soejima K, Kudoh S, et al. Extended survival observed in adoptive activated T lymphocyte immunotherapy for advanced lung cancer: Results of a multicenter historical cohort study [J]. Cancer Immunol Immunother, 2012, 6l(10): 781-790.
20. Hunder NN, Wallen H, Cao J, et al. Treatment of metastatic melanoma with autologous CD4 + T cells against NY-ESO-1 [J]. N Engl J Med, 2008, 358(25): 2698-2703.
21. Kawaoka T, Oka M, Takashima M, et al. Adoptive immunotherapy for pancreatic cancer: Cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1 [J]. Oncol Rep, 2008, 20(1): 155-163.
22. Chu CS, Boyer J, Schullery DS, et al. Phase I/H randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission [J]. Cancer Immunol Immunother, 2012, 6l(5): 629-641.
23. Yang Z, Zhang Q, Xu K, et al. Combined therapy with cytokine-Induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor model [J]. PLoS One, 2012, 7(9): e44802.
24. Bernhard H, Neudorfer J, Gebhard K, et al. Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treat- ment of R2-over expressing breast cancer [J]. Cancer Immunol Immunother, 2008, 57(2): 271-280.
25. Guo Z, Liu H, He XP, et al. A clinical study of cytokine-induced killer cells for the treatment of refractory lymphoma [J]. Oncol Lett, 2011, 2(3): 531-536.
26. Mesiano G, Todorovic M, Gammaitoni L, et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors [J]. Expert Opin Biol Ther, 2012, 12(6): 673-684.
27. Sangiolo D. Gytokine induced killer cells as promising immunotherapy for solid tumors [J]. J Cancer, 2011, 2: 363-368.
28. Galon J, Gostes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome [J]. Science, 2006, 313 (5795): 1960-1964.
29. Leffers N, Gooden MJ, de Jong RA, et al. Pro gnostic significance of tumor- infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer [J]. Cancer Immunol Immunother, 2009, 58(3): 449-459.
30. de Jong RA, Leffers N, Boezen HM, et al. Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer [J]. Gynecol Oncol, 2009, 114 (1): 105-110.
31. Chen J, Li HY, Wang D, et al. Human dendritic cells transfected with amplified M U C1 mRN A stimulate cytotoxic T lymphocyte responses against pancreatic cancer in vitro [J]. J Gastroenterol Hepatol, 2011, 26(10): 1509-1518.
32. Chen L, Qiu M, He W, et al. Functional study of immature dendritic cells co-transfected with IL-10 and TGF-beta 1 genes in vitro [J]. Mol Biol Rep, 2012, 39(6): 6633-6639.